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Aim Biological therapies for ischaemic heart disease require efficient, safe, and affordable intramyocardial delivery. Integration
of multiple imaging modalities within the fluoroscopy framework can provide valuable information to guide these pro-
cedures. We compared an anatomo-electric method (LARCA) with a non-fluoroscopic electromechanical mapping
system (NOGAw). LARCA integrates selective three-dimensional-rotational angiograms with biplane fluoroscopy. To
identify the infarct region, we studied LARCA-fusion with pre-procedural magnetic resonance imaging (MRI), dedicated
CT, or 18F-FDG-PET/CT.
Methods
and results
We inducedmyocardial infarction in 20 pigs by 90-min LADocclusion. Sixweeks later,we comparedperi-infarct delivery
accuracy of coloured fluospheres using sequential NOGAw- and LARCA-MRI-guided vs. LARCA-CT- and LARCA-18F-
FDG-PET/CT-guided intramyocardial injections. MRI after 6 weeks revealed significant left ventricular (LV) functional
impairment and remodelling (LVEF 31+ 3%, LVEDV 178+ 15 mL, infarct size 17+ 2% LV mass). During NOGAw-
procedures, three of five animals required DC-shock for major ventricular arrhythmias vs. one of ten during LARCA-
procedures. Online procedure time was shorter for LARCA than NOGAw (77+ 6 vs. 130+3 min, P, 0.0001).
Absolute distance of injection spots to the infarct border was similar for LARCA-MRI (4.8+0.5 mm) and NOGAw
(5.4+0.5 mm). LARCA-CT-integration allowed closer approximation of the targeted border zone than LARCA–
PET (4.0+0.5 mm vs. 6.2+0.6 mm, P, 0.05).
Conclusion Three-dimensional -rotational angiography fused with multimodal imaging offers a new, cost-effective, and safe strategy
to guide intramyocardial injections. Endoventricular procedure times and arrhythmias compare favourably to NOGAw,
without compromising injection accuracy. LARCA-based fusion imaging is a promising enabling technology for cardiac
biological therapies.
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Introduction
Development of protein- and cell-based therapy for advanced is-
chaemic heart disease requires efficient and widely applicable
intramyocardial delivery strategies. To date, the NOGAw-platform
(BiosenseWebster) is a reference technique to guide percutaneous
intramyocardial injections of biologicals into the ischaemic
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myocardium.1–4 NOGAw is able to differentiate regions of non-
viable, viable ischaemic/hibernating, and viable healthy myocardium,
based on real-time acquisition of a three-dimensional (3D) endoven-
tricular electromechanical map.5–7 NOGAw-guided injection strat-
egies are thus based on real-time functional data (both endocardial
potential and regional contraction). This strategy requires consider-
able experience, is costly, provides only limited anatomical feedback
andmayhave less discriminatory power in identifying non-transmural
scar areas.8 Injection strategies based on structural feedback could
thus offer a promising alternative.
Magnetic resonance imaging (MRI) allowsunparallelledmyocardial
tissue contrast discrimination but the need for complex XMR-
facilities and MRI-compatible, coiled endovascular catheters remain
obstacles.9,10 The possibility of integrating pre-procedural MRI
images with live X-ray fluoroscopy circumvents these limitations.11
Alternatively, the location and extent of the infarct region could be
derived from computed tomography (CT) or 18F-FDG positron
emission tomography (PET) in MRI-incompatible patients.
Here, we report the safety, feasibility, and accuracy of a novel
mapping technique as an extension to our leuven augmented reality
catheter ablation system (LARCA) currently used in our centre to
guideelectrophysiological ablationprocedures in all heart chambers.12
LARCA integrates selective 3D rotational angiograms (3D-RA) with
live biplane fluoroscopy in an augmented reality environment. To
guide endomyocardial injections towards the infarct border zone,
left ventricular (LV)-3D-RAs were integrated with manual infarct
delineations, derived from pre-procedural imaging modalities (MRI,
CT, or PET/CT). This methodology was investigated in a non-
inferiority comparative study with the NOGAw-platform.
Methods
Study design
The studywas approved by the EthicsCommittee forAnimal Experimen-
tation (KULeuven, Belgium), and was performed in accordance with the
Guide forCareandUseof LaboratoryAnimals (NIH).MRI, dedicatedCT,
or 18F-FDG-PET/CT was performed 6 weeks after infarct induction.
Fluorescent microspheres were injected 4+1 days after image acquisi-
tion. In a first set of five animals, head-to-head comparison between a
NOGAw and LARCA-MRI-guided injection strategy was performed.
In a second set of experiments, we injected three animals using
LARCA-CT-integration and three animals using LARCA-18F-FDG-PET/
CT-integration (Figure 1). All animals were euthanized by i.v. propofol
overdose and oversaturated potassium chloride.
Infarct induction
Domestic pigs, weighing 25–30 kg, were pre-medicated with amiodar-
one 400 mg daily from Day 214 to 27 and 200 mg daily from Day 27
until infarct induction. Pre-treatmentwith aspirin 300 mg and clopidogrel
300 mg was initiated at Day 21. Pigs were pre-anaesthetized with
tiletamine/zolazepam (8 mg/kg i.m.) and xylazine hydrochloride (2.5 mg/kg
i.m.), followed by a continuous infusion of propofol (10 mg/kg/h) and
remifentanil (0.3 mg/kg/min). The animals were intubated and ventilated
with a 1 : 1 mixture of air and oxygen. Invasive blood pressure and ECG
were monitored during the whole procedure. Myocardial infarction was
induced in 20 pigs using a 90-min stented balloon inflation in the proximal
left anterior descending coronary artery (2.5–3.5× 8, Presilion Plus,
Cordisw). Aspirin and clopidogrel daily treatment was continued until
euthanasia 6 weeks later.
MRI cine-angiography and delayed
enhancement
Cardiac MRI (3 T Siemensw Trio) was performed 6 weeks after infarct
induction using the Siemens Numaris-4 software, ECG-triggering, and
cardiac-dedicated surface coils. The LV was completely encompassed
Figure 1: Experimental study design: a total of 20 pigs were infarcted. Endomyocardial injections were performed both by NOGAw and
LARCA-MRI-guidance in four pigs. In an additional subset of six animals, three pigs were injected using LARCA-CT-guidance and another three
pigs using LARCA-PET-guidance.
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bycontiguous 6-mmthick short-axis slices, and global function and infarct
area (Figure 2A–C) analysed as described previously.13
Dedicated CT
Cardiac128-sliceCT (Siemens SomatomDefinition Flash, SiemenswAG,
Erlangen, Germany) was performed 6 weeks after infarct induction.
CT was acquired after i.v. administration of 60 mL of a non-diluted
iodine contrast agent at a rate of 5 mL/s. Bolus triggering was performed
in the ascending aorta to initiate image acquisition (detector collimation:
128 × 0.6 mm,Voltage: 120 kV, tube current: 320 mAs).All studieswere
performed using ventilation-stop and ECG-triggering, allowing recon-
struction of both systolic and diastolic phase of the cardiac cycle and
infarct delineation based on transmural end-diastolic wall thickness
(Figure 2D).
18F-FDG-PET/CT
Six weeks after infarct induction, animals were fasted overnight and a
hyperinsulinaemiceuglycaemic clampwasperformedbefore tracer injec-
tion and acquisition of 18F-FDG-PET/CT.14 Insulin (0.08 units/kg/h) was
continuously infused and glycaemia was monitored every 2–5 min.
Glucose 20%, supplemented with KCl (80 mEq/L), was administered to
achieve a steady-state glycaemia between 70 and 110 mg/dL. Fifteen
minutes thereafter, 370 MBq 18F-FDG was injected i.v., followed by a
low-dose CT scan for attenuation correction. A 60-min static PET-
image of the myocardium was acquired 20 min later (HiRez Biograph
16, Siemensw, Knoxville) (Figure 2E). Images were reconstructed using
OSEM.
NOGAw-mapping
Electro-mechanical maps, based on an average of 122+ 13 mapping
points encompassing the whole LV, were obtained with the NOGAw-
system, using a Myostarw injection catheter (Biosense Webster). The
infarct region was identified using stringent bipolar voltage (BPV
,0.5 mV) and local linear shortening (LLS) criteria. Regions with
preserved linear shortening and BPV .1.5 mV were defined as healthy
myocardium (Figure 3).
LARCA
Pre-procedural MRI, CT, and PET images were manually delineated on
an offline workstation to obtain segmentation surfaces for endocard,
aortic arch, and myocardial infarct region, corresponding to the
cardiac phase resembling interventional LV-3D-RA. For MRI-delayed-
enhanced imaging, non-rigid image registration techniques were applied
to transform the infarct surface to the interventional reference phase.
Hence a single phase 3D LV-model is obtained, reflecting wall thickness,
infarct size, and infarct location.During the intervention, a LV-3D-RAwas
acquired with a single C-arm rotation, as reported before.15 Combined
rapid pacing in both right ventricle and right atrium (200 ms cycle
length) was used to obtain a quasi cardiac standstill in order to reduce
motion artefacts. Following online reconstruction of the 3D-dataset
Figure2: Identificationof the infarct regiononpre-procedural imaging: 6weeks aftermyocardial infarction, cine-MRI images at end-diastole dem-
onstrate important LV-dilatation and anteroseptal wall thinning (A) in comparison with sham animals (B). The infarct region is clearly identified
between arrows on MRI-delayed enhancement (C), dedicated CT (D) and 18F-FDG-PET/CT short-axis views (E).
Figure3: NOGAw-map: 3DBPVmap (A) and corresponding bull’s eye plots representing BPV (B) and LLS (C). The different injection spots in the
peri-infarct border are indicated as black dots on the bull’s eye representations. Injections were directed towards the peri-infarct border region
based on a BPV between 0.5 and 1.5 mV.
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obtained from the X-ray projection images, an endocast surface
segmentation of the LV and aortic arch was generated. The latter LV-
surface was registered with the corresponding MRI, CT, or PET-based
LV-segmentation, using an iterative closest points-like (ICP) surface regis-
tration technique.16 This approach resulted in a detailed, high-resolution
3D endocardial surface model, including MRI, CT, or PET-derived infor-
mation about wall thickness and infarct location in a single co-ordinate
system. This model was subsequently integrated with and semi-
transparently projected on live biplane orthogonal fluoroscopy images,
as previously described.12,17 The resulting augmented reality visualization
was presented to the operator on twomonitors in the catheterization la-
boratory, hence providing real-time feedback to safely navigate the cath-
eter towards the infarct border (Figure 4) (Supplementary data online,
Video S1).
Intramyocardial injections
A pre-defined goal of 20 injections of 200 mL fluorescently labelled
microspheres was performed 6 weeks after infarct induction using the
Myostarw injection catheter (Biosense Webster). Needle length was
adjusted to 3–4 mm, depending on the wall thickness of the peri-infarct
border, assessed by pre-procedural MRI, CT, or PET.
In an initial set of five animals, injections of orange fluospheres (Invitro-
genw, 18+ 1 spots/animal)were delivered usingNOGAw-guidance, fol-
lowed by LARCA-MRI-guided injections of green fluospheres (19+
1 spots/animal). NOGAw-guided endomyocardial injections were direc-
ted towards the peri-infarct border region based on a BPV between 0.5
and 1.5 mV (Figure 3). LARCA-MRI-guided endomyocardial injections
were directed towards the peri-infarct border region, identified from
pre-procedural late-enhanced MRI (Figure 2C).
In additional six animals, endomyocardial injectionsweredeliveredusing
LARCA-CT (n ¼ 3;17+2 spots/animal) or LARCA-18F-FDG-PET/CT
(n ¼ 3; 20+0 spots/animal) integration. Infarct delineation was based
on end-diastolic wall thinning (Figure 2D) in the former and 18F-FDG
uptake (Figure 2E) in the latter group of animals.
Processing and analysis
After euthanasia, the heart was embedded in 5% agarose solution, sec-
tioned in contiguous 5-mm slices from the apex to the base, and
stained with 2,3,5-triphenyltetrazolium chloride (TTC) allowing infarct
identification. All slices were photographed under normal and UVA
light on both sides and pictures subsequently co-registered to obtain
an ex vivo 3D-stack of the LV (Supplementary data online, Figure S1).
TTC-defined infarct border, together with endocardial and epicardial
surfaces were manually delineated. UVA-illumination allowed localiza-
tion and differentiation of orange and green fluosphere injection spots.
The distance from endomyocardial injection spots towards the
TTC-defined infarct border was semi-automatically quantified in a 3D
co-ordinate system and injection accuracy was compared in the apical,
mid, and basal third of the LV.
Statistical analysis
All data arepresented asmeans+ SEM. Intergroupdifferenceswereana-
lysed using two-tailed unpaired t-tests. P, 0.05 was considered
Figure 4: LARCA-algorithm: pre-procedural infarct and endocard delineations are registered with a periprocedurally acquired 3D rotational
angiography using a surface based fusion algorithm. The resulting 3D-model is presented to the operator as a semi-transparent overlay on conven-
tional live biplane fluoroscopy in an orthogonal configuration. The tasks indicated in green are completed pre-procedurally, while the tasks indicated
in blue are performed during the intervention.
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statistically significant. All analyses were performed with Prism 5.0a
(GraphPad Software, Inc.).
Results
Animal model
Myocardial infarctionwas induced in 20 animals, of which 14 survived
to 6 weeks. The rise in troponin-I and CK-Mb at 2 h reperfusion was
560+ 77 (≤0.13) and 122+43 mg/L (≤3.5), respectively. Follow-
ingMRI or CT analysis at 6week follow-up, three pigs were excluded
because of limited myocardial infarction. In comparison with sham
animals (n ¼ 3), cine-MRI at 6 weeks confirmed significant functional
impairment and LV-remodelling in the infarcted pigs (n ¼ 11): LVEF
31+ 3%, LVEDV 178+ 15 mL, and LVESV 122+10 mL (Table 1).
The region of delayed enhancement composed 17+2% of the
total LV-mass. LV-volumes obtained by MRI correlated closely to
thevolumesassessedbyNOGAw in the subsetof animals undergoing
NOGAw-guided injection procedures (n ¼ 5): LVEF 31+ 1%,
LVEDV 199+11 and LVESV 138+9 mL.
Intramyocardial injections
In the first series of experiments, an average of 18+1 injections per
pig were delivered using NOGAw, whereas 19+ 1 injections were
delivered afterwards in the same animals using LARCA-MRI. Electric-
al irritability of some peri-infarct regions in two of five animals pre-
cluded to deliver the pre-defined number of 20 injections, equally
distributed around the infarct. In total, 89 and 75 injections were
delivered using NOGAw and LARCA-MRI respectively, of which
49 NOGAw-guided injection spots (55%) and 42 LARCA-MRI-
guided injection spots (56%) could be localized in the 5 mm thick
ventricular tissue slices. LARCA-MRI and NOGAw enabled spatial
confinement of .90% of injection spots ,1 cm from the targeted
infarct border (Table 2). The mean absolute distance of the injection
spots to the infarct border was 4.8+0.5 and 5.4+0.5 mm for
LARCA-MRI and NOGAw, respectively, P ¼ 0.40 (Figure 5). We
also analysed the mean signed distance, with negative values repre-
senting localizations towards the infarct core, and positive values
representing localizations at the opposite side of the infarct border,
towards remotemyocardium. Themean signed distance of the injec-
tion spots to theTTC-defined infarctborderwas20.6+ 0.9 mmfor
NOGAw and 22.3+ 0.8 mm for LARCA-MRI-guided injections,
P ¼ 0.19 (Figure 6).
In an additional six animals, a total of 52 and 60 injections were
delivered utilizing LARCA-CT or LARCA-PET, respectively. Induc-
tion of sustained VT and VFib after 13 injections precluded to
deliver a pre-defined goal of 20 injections in one animal, injected
using LARCA-CT-guidance. In total, 32 LARCA-CT (62%)- and 44
LARCA-PET (73%)-guided injection spots could be localized ex
vivo. Delivery using LARCA-CT-integration allowed the closest
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 MRI-data 6 weeks after myocardial infarction
MRI LVEDV
(mL)
LVESV
(mL)
LVEF
(%)
DE
(% LV)
Sham (n ¼ 3) 116+6 48+2 58+4 0
6w post MI
(n ¼ 11)
178+15a 122+10a 31+3a 17+2a
Six weeks after myocardial infarction, MRI-analysis demonstrates important
functional impairment and LV-remodelling in comparison with sham animals.
a P-value ,0.05.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Injection accuracy and depth
NOGA LARCA-MRI LARCA-CT LARCA-PET
Injections ≤5 mm of infarct border (% total) 51% 60% 66% 43%
Injections ≤10 mm of infarct border (% total) 90% 93% 97% 84%
Average injection depth (mm) 2.5+0.3 2.9+0.4 3.2+0.4 2.7+0.4
Average wall thickness (mm) 9.1+0.4 9.7+0.5 10.1+0.6 8.8+0.4
Percentage of the injection spots localized≤5 and≤10 mmof the targeted infarct border (absolute distance). Average injection depth and average post-mortemwall thickness at the
corresponding injection localizations.
Figure 5: Absolute distance of the injection spots to the infarct
border: absolute distance of the different injection spots to the
TTC-defined infarct border. These values do not take into
account whether the injections are localized at the infarcted or
remote side of the targeted infarct border.
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approximation of the targeted infarct border zone with the smallest
distribution between the different injection spots (Figure 5). The
mean absolute distance to the infarct border was 4.0+ 0.5 mm for
LARCA-CT-guided injection spots and 6.2+0.6 mm for LARCA-
PET-guided injection spots, P ¼ 0.006 (Figure 5). Moreover, 97% of
all LARCA-CT-guided injections and 84% of all LARCA-PET-guided
injections were localized ,1 cm from the infarct border (Table 2).
In comparison with NOGAw (P ¼ 0.038) and LARCA-MRI (P ¼
0.0003), LARCA-CT-guided injections were clustering more
outside the actual infarct core towards remote, non-ischaemic myo-
cardium (Figure 6). Themean signed distance of the injection spots to
the infarct border was 2.2+ 0.8 mm for LARCA-CT-guided injec-
tions and 0.0+1.1 mm for LARCA-PET-guided injections.
Obtaining perpendicular wall contact and a stable catheter pos-
itionwasmore challenging for endomyocardial injection targets loca-
lized at the base of the LV. Thiswas confirmedby regional differences
in injection efficiency. For all LARCA-modalities combined, only
36.7% of the planned targets localized at the base of the LV could
be identified on post-mortem sections. In comparison, 66.7% of
the apical and 64.6% of themid-ventricular targets could be localized
ex vivo (Supplementary data online, Table S1). Despite the difficulties
toobtain a stable catheter position for intramyocardial delivery at the
base of the LV, targeting accuracy remained unchanged if such a pos-
ition could actually be achieved (Supplementary data online, Figure S2).
No differences were noted in injection depth between the differ-
ent guiding strategies (Table 2, Supplementary data online, Figure S3).
Average ex vivo defined injection depth was 2.8+ 0.2 mm. Average
post-mortem transmural wall thickness at the corresponding injec-
tion sites was 9.4+ 0.2 mm. More than 84% of the injections were
localized in the inner 50% of the total wall thickness, with a median
injection depth corresponding to 23% endo-epicardial transmurality.
During NOGAw-procedures, three of five animals required DC-
shock for major ventricular arrhythmias vs. one of ten during
LARCA-procedures. One animal died after 14 NOGAw-guided
injections, due to intractable VFib. None of the animals showed
signs of ventricular perforation, pericardial tamponade, intramural
hematomas, aortic valve injury, or aortic/coronary dissection
during careful post-mortem examination. Average cardiac marker
release, 2 h after 20 intramyocardial injections, was 2.38+
0.22 mg/L for troponin-I (≤0.13) and 4.5+0.9 mg/L for CK-Mb
(≤3.5).
Online procedure time was significantly shorter for LARCA-
procedures in comparison with NOGAw. Introduction of pacing
catheters, acquisition of a LV-3D-RA and subsequent online fusion
with pre-procedural MRI, CT, or PET datasets accounted for 46+
6 min. Average procedure time for LARCA-guided injections was
31+ 4 min. A NOGAw-map, encompassing the whole LV (122+
13 mapping points), was reconstructed in 75+ 5 min. Subsequent
procedure time for NOGAw-guided injections was 55+4 min.
This accounted for a total online procedure time of 77+6 min for
LARCA vs. 130+ 4 min for NOGAw, P, 0.0001.
Discussion
We report a novel mapping strategy to guide endomyocardial injec-
tions into the infarcted heart, offering a safe, fast, and accurate alter-
native to existing non-fluoroscopic electromechanical mapping
systems. LARCA-guidance is based on in-house developed fusion
of pre-procedural multimodal imaging of the heart with 3D-RA
during radiofrequency catheter ablation (LARCA). In this study, we
characterized the use of this anatomo-electric approach for targeted
injectionsof fluorescentmicrospheres in the infarctborder zone.We
observed less arrhythmic side-effects and shorter online procedure
times than the electromechanical mapping standard NOGAw,
without compromizing on injection accuracy. Both LARCA-MRI
and NOGAw enabled spatial confinement of .90% of injection
spots,1 cm from the targeted infarct border. The median injection
depthdidnotextendbeyondtheendocardial 25%of the total LV-wall
transmurality, a pre-requisite for safe intramyocardial delivery in is-
chaemic heart disease.
Acquisition of a LV-3D-RA integrated with pre-procedural multi-
modal imaging obviates the need for multiple and prolonged endo-
cardial contact time, as required to construct a complete NOGAw-
map. Hence, the risk of inducing ventricular arrhythmias in inherently
vulnerable and irritable ischaemic myocardium was also significantly
reduced, although the concomitant anti-arrhythmic beta-blocker
and/or amiodarone use were not different between groups. Finally,
since manual delineations are performed on an offline workstation
prior to the procedure, they do not interfere with online procedure
time, which is therefore significantly shorter.
Figure 6: Signed distance of the injection spots to the infarct
border: signed distance of the different injection spots to the
TTC-defined infarct border. Negative values represent localiza-
tions at the infarcted side of the infarct border, whereas positive
values represent injections at the opposite side, towards remote
myocardium.
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Despite the highly dynamic environment of the LV, vastmajority of
the injections was localized within 1 cm of the targeted infarct
border, irrespective of the fusion modality used. For the evaluation
of targeting accuracy on post-mortem TTC-stained sections, the
minimal slice thickness of 5 mm limited tissue penetration of UVA
light, and hence reduced the number of identifiable injection spots.
Of note, LARCA-CT-guided injections showed a greater clustering
pattern towards healthy, remote myocardium. LARCA–PET-guided
injections in contrast, showed a greater dispersion across the infarct
border, potentially caused by the lesser spatial resolution and static/
ungated acquisition of the PET-images obtained.
Delivery route is a major determinant of cell/protein retention in
the injured myocardium. Transvascular cell administration has been
mainly implemented in the (sub)acute phase after myocardial infarc-
tion, as it relies on up-regulation of cell adhesion molecules and
homing signals for optimal retention. In contrast, in advanced ischae-
mic heart disease, the occurrence of collateral flow, severe coronary
stenoses, and/or chronic total occlusions, together with loss of
homing signals and down-regulation of adhesion molecules, limits
intracoronary delivery efficiency. Hence, intramyocardial delivery
hasbeenproposedas thepreferreddelivery strategy.Whereas trans-
epicardial injections are limited to patients scheduled for cardiac
surgery, transendocardial injections offer a less invasive treatment
strategy as a stand-alone procedure. To date, the NOGAw-platform
is established as a reference technique to guide transendocardial
injections into the ischaemic myocardium, allowing differentiation
of ischaemic, viable myocardium, based on electromechanical
mapping. Limited availability and experience with NOGAw through-
out most cardiac centres, in combination with its considerable cost,
hamper widespread clinical application of transendocardial injection
strategies.
In contrast to NOGAw, our mapping strategy allows guidance of
endomyocardial injections into ischaemic areas, based on anatomical
andstructural feedback, derived from imagingmodalities readily avail-
able inmost cardiac centres. Fusion of pre-procedural late-enhanced
MRI imageswith a LV-3D-RAprovides theoperator a 3D-modelwith
both high soft tissue contrast discrimination and high spatial reso-
lution. In contrast to thework presented by de Silva et al.,11 our algo-
rithmallowedco-registrationof thepre-proceduralmodelwithin the
fluoroscopy frameworkwithout the use of external fiducial markers.
Accurate demarcation of viable from non-viable myocardium is crit-
ically important for safe andeffectivebiological therapies aimed at en-
hancing cardiac repair.Ourdata indicate that this is alsopossible using
pre-procedural CT or 18F-FDG-PET/CT in an MRI-incompatible
patient population.
In addition to providing highly detailed anatomical information, the
system allows integration of functional feedback. Endocardial poten-
tials and activation times, acquired during selective voltage mapping
of a region of interest, can be transferred onto the 3D anatomical
model.17 This data can be presented to the operator as a colour-
coded map on the surface of the model. Moreover, additional
useful information, including MRI-derived regional contraction and
wall thickness, could also be annotated to the model.
Some limitations need to be considered. First, LARCA does not
eliminate the need for iodine contrast and X-ray imaging. The effect-
ive radiation dose to acquire a single 3D-RA is 6.6+1.8 mSv, which
can be reduced up to 1.2–2.6 mSv through manual collimation of
the radiationbeamandrecentoptimizationofour3D-RA-acquisition
protocol.18 In comparison, radiation doses for conventional, ungated
cardiac CT range between 8.5 and 16 mSv for 16-slice, 32-slice
or dual-source CT.19,20 Secondly, integration of pre-procedural
imaging and manual segmentation may increase cost, which needs
to be evaluated against the investment in dedicated hardware and
specialized catheters for existing electromechanical mapping
systems. Thirdly, administration of rapid pacing requires general an-
aesthesia, but recent optimizations in 3D-RA acquisition have
allowed to acquire these images during conventional slow pacing
protocols.
In conclusion, LARCA-guided injection procedures in a clinically
representative model of ischaemic heart disease were associated
with equivalent injection accuracy, less arrhythmias, and shorter
online procedure times then NOGAw. LARCA offers a new and
promising strategy to accurately guide intramyocardial injections
towards the peri-infarct region, based on technology and experience
readily available in most cardiac centres. Since LARCA-technology
does not rely on dedicated hardware or specialized, costly catheters,
it offers a favourable alternative to existing electromechanical
mapping systems, facilitating delivery of future biological therapies
to patients with ischaemic heart disease.
Supplementary data
Supplementary data are available at European Heart Journal –
Cardiovascular Imaging online.
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